Izicopan shows low reactive metabolite formation, suggesting better safety profile than avacopan.

InflaRx announced pre-clinical data showing that izicopan, an investigational oral C5aR1 inhibitor, produces minimal reactive metabolites in human liver microsomes, indicating a potentially safer profile compared to the marketed drug avacopan. This low bioactivation suggests fewer safety risks, supporting izicopan's differentiation in its drug class. Clinical data so far show izicopan is well tolerated and effective in reducing inflammation in diseases like hidradenitis suppurativa and chronic spontaneous urticaria. These findings position izicopan as a promising next-generation anti-inflammatory treatment, pending further clinical validation.